XFOR — X4 Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $317.27m
- $186.06m
- $35.11m
U.S. STOCKS ON THE MOVE-Oruka Therapeutics, Regeneron, natgas companies
Brief: X4 Pharmaceuticals Announces Restructuring Of Business Operations Designed To Drive Long-Term Value Creation
X4 Pharmaceuticals to cut workforce by half, shares up
Brief: X4 Pharmaceuticals Files For Offering Of Up To 59.9 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
X4 Pharmaceuticals Inc expected to post a loss of $4.34 a share - Earnings Preview
Brief: X4 Pharmaceuticals Enters Purchase Agreement With Lincoln Park - SEC Filing
Brief: X4 Pharmaceuticals Granted Fast Track Designation For Mavorixafor For Treatment Of Chronic Neutropenia By US FDA
Brief: X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress
X4 Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: X4 Pharmaceuticals Full Enrollment On Track For 3Q Or 4Q 2025 And Top-Line Data In 2H 2026
X4 Pharmaceuticals Inc expected to post a loss of $4.44 a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Reverse Stock Split
X4 Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: X4 Pharmaceuticals Q4 Net Income USD -39.821 Million
X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals And Taiba Rare Announce Exclusive Agreement For The Distribution And Commercialization Of Xolremdi® (Mavorixafor) In Whim Syndrome In Select Middle East Countries
Brief: X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)